Clinical trials: Asthma Patients
Severe Eosinophilic Asthma
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of…
- Trial name
- ORBE (NCT04126499)
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Asthma
Feasibility Trial of a Mobile Adherence Tool for Adolescents With Asthma
The purpose of this study is to assess the feasibility of using a mobile health intervention to improve adherence to asthma medication among adolescents in an urban clinic setting.
- Trial name
- NCT02426801
- Testing
- Inhaler sensor, Mobile application for asthma adherence
- Volunteers
- 16 people
- Sponsor
- CoheroHealth
Asthma
Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres
Retrospective secondary data collection observational chart review study. Data collection and analysis will be performed on a cohort of patients who have previously been enrolled on the BPAP.
- Trial name
- BPAP (NCT05932849)
- Testing
- Benralizumab
- Where
- 8 sites in United Kingdom
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Severe Asthma
Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes
Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-agonists.
- Trial name
- Betreat (NCT07159295)
- Where
- 16 sites in Portugal
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Asthma
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
- Trial name
- NCT01836471
- Testing
- QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Where
- 76 sites in United States, Belgium and 8 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
Despite availability of treatments and published guidelines, subjects may have asthma that is inadequately controlled. GlaxoSmithKline is currently developing a once-daily 'closed' triple therapy of an Inhaled…
- Trial name
- NCT03184987
- Testing
- FF/UMEC/VI 100/62.5/25 mcg, FF/UMEC/VI 200/62.5/25 mcg, Salbutamol
- Where
- 13 sites in Japan
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose…
- Trial name
- NCT01396278
- Testing
- Fluticasone propionate, BI 54903
- Where
- 37 sites in United States
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Asthma
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.
- Trial name
- STAR (NCT00445107)
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
- Volunteers
- 198 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma, COPD
A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)
This study will compare the patient handling of Flutiform® pMDI (pressurised metered dose inhaler) and a breath activated device (BAI).
- Trial name
- NCT01739387
- Testing
- Flutiform® pMDI and Breath Actuated Inhaler (BAI)
- Where
- 2 sites in United Kingdom
- Volunteers
- 332 people
- Sponsor
- Mundipharma Research Limited
Asthma
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
- Trial name
- NCT01928771
- Testing
- Benralizumab
- Where
- 275 sites in United States, Australia and 15 more
- Volunteers
- 2,681 people
- Sponsor
- AstraZeneca
Asthma
Montelukast Back to School Asthma Study (0476-340)
This study, in children with chronic asthma, evaluates the number of days of worsening asthma during 8 weeks of treatment with montelukast after treatment is started for the first day of school.
- Trial name
- NCT00461032
- Testing
- montelukast
- Volunteers
- 1,162 people
- Sponsor
- Organon and Co
Asthma
Efficacy of QAX576 in Asthma
The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
- Trial name
- NCT01130064
- Testing
- QAX576
- Where
- 52 sites in United States, Argentina and 5 more
- Volunteers
- 259 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU), Allergic Asthma
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
ROLL'YN-OMA is a real-world study in patients receiving standard biologic therapies who have been in control and/or remission of their disease for at least 3 months and whose physician has independently decided, within the…
- Trial name
- ROLL'YN-OMA (NCT07425639)
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
Asthma
Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients
This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of metered dose inhaler (MDI) of Albuterol (Treatment T)…
- Trial name
- NCT00635505
- Testing
- albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA)
- Where
- 42 sites in United States
- Volunteers
- 300 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting
Primary Objective: To describe dupilumab health-related quality of life (HRQoL) effectiveness at 52 weeks compared to baseline. Secondary Objectives: To describe dupilumab HRQoL effectiveness at 12 and 24 weeks compared to…
- Trial name
- PROVERB (NCT06018441)
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Sanofi
Asthma
MK0476 Study in Adult Patients With Acute Asthma (0476-322)
This study evaluates the efficacy and safety of MK0476 intravenous administration in adult patients with acute asthma.
- Trial name
- NCT00229970
- Testing
- montelukast sodium
- Volunteers
- 225 people
- Sponsor
- Organon and Co
Healthy, Asthma
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.
- Trial name
- NCT01310322
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
BALLOON (Corticosteroid/laBA inhaLers in adoLescents' Asthma: Assessment Of Patients satisfactiON) Study
Patients' satisfaction with their asthma medication devices is usually decided by using properly designed questionnaires. These questionnaires are to be used to evaluate patients' opinion, which is considered very important for…
- Trial name
- BALLOON (NCT01708486)
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.